ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,866,760 | -7.9% | 248,717 | +19.2% | 0.01% | -10.0% |
| Q2 2023 | $9,626,731 | +35.5% | 208,687 | +17.8% | 0.01% | +42.9% |
| Q1 2023 | $7,106,522 | -3.7% | 177,220 | +11.2% | 0.01% | -12.5% |
| Q4 2022 | $7,381,296 | +26.2% | 159,320 | +12.8% | 0.01% | +14.3% |
| Q3 2022 | $5,849,000 | -30.7% | 141,255 | -0.2% | 0.01% | -22.2% |
| Q2 2022 | $8,446,000 | -5.0% | 141,555 | +15.6% | 0.01% | +12.5% |
| Q1 2022 | $8,890,000 | +5.2% | 122,427 | +21.9% | 0.01% | +100.0% |
| Q4 2021 | $8,447,000 | +29.3% | 100,444 | +38.7% | 0.00% | 0.0% |
| Q3 2021 | $6,532,000 | -26.2% | 72,436 | -21.9% | 0.00% | -20.0% |
| Q2 2021 | $8,846,000 | +15.0% | 92,768 | +37.3% | 0.01% | +25.0% |
| Q1 2021 | $7,695,000 | -40.8% | 67,588 | -28.0% | 0.00% | -33.3% |
| Q4 2020 | $13,000,000 | +119.3% | 93,906 | +30.2% | 0.01% | +50.0% |
| Q3 2020 | $5,928,000 | -19.3% | 72,135 | -23.2% | 0.00% | -20.0% |
| Q2 2020 | $7,345,000 | +3.2% | 93,910 | -41.4% | 0.01% | -16.7% |
| Q1 2020 | $7,120,000 | +25.0% | 160,238 | +20.1% | 0.01% | +50.0% |
| Q4 2019 | $5,697,000 | +48.8% | 133,369 | +49.0% | 0.00% | +33.3% |
| Q3 2019 | $3,828,000 | +34.8% | 89,504 | +100.1% | 0.00% | 0.0% |
| Q2 2019 | $2,840,000 | -0.8% | 44,727 | +8.3% | 0.00% | 0.0% |
| Q1 2019 | $2,863,000 | +67.9% | 41,290 | +5.3% | 0.00% | +50.0% |
| Q4 2018 | $1,705,000 | -43.3% | 39,215 | -0.4% | 0.00% | -33.3% |
| Q3 2018 | $3,005,000 | -26.8% | 39,373 | -26.3% | 0.00% | -25.0% |
| Q2 2018 | $4,104,000 | +39.2% | 53,406 | -7.7% | 0.00% | +33.3% |
| Q1 2018 | $2,949,000 | +26.2% | 57,847 | +14.8% | 0.00% | +50.0% |
| Q4 2017 | $2,337,000 | -65.7% | 50,390 | -60.6% | 0.00% | -71.4% |
| Q3 2017 | $6,819,000 | -13.2% | 128,023 | +1.3% | 0.01% | -12.5% |
| Q2 2017 | $7,852,000 | -19.8% | 126,413 | -12.5% | 0.01% | -11.1% |
| Q1 2017 | $9,789,000 | +18.0% | 144,442 | +22.5% | 0.01% | +12.5% |
| Q4 2016 | $8,293,000 | -2.1% | 117,940 | -1.2% | 0.01% | 0.0% |
| Q3 2016 | $8,469,000 | +22.7% | 119,376 | -15.4% | 0.01% | 0.0% |
| Q2 2016 | $6,905,000 | +28.1% | 141,187 | +65.8% | 0.01% | +33.3% |
| Q1 2016 | $5,390,000 | -14.9% | 85,149 | +50.9% | 0.01% | -14.3% |
| Q4 2015 | $6,333,000 | +21.1% | 56,444 | +4.0% | 0.01% | +16.7% |
| Q3 2015 | $5,229,000 | -2.1% | 54,297 | +4.1% | 0.01% | +20.0% |
| Q2 2015 | $5,342,000 | +155.5% | 52,177 | +54.9% | 0.01% | +150.0% |
| Q1 2015 | $2,091,000 | +135.2% | 33,677 | +66.2% | 0.00% | +100.0% |
| Q4 2014 | $889,000 | +38.5% | 20,265 | +78.5% | 0.00% | 0.0% |
| Q3 2014 | $642,000 | – | 11,352 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |